Abstract: Disclosed in the present invention are a nitrogen-containing heterocyclic compound, and a preparation method therefor, an intermediate thereof, and an application thereof. The present invention provides a nitrogen-containing heterocyclic compound as represented by formula (I), a stereoisomer thereof, or a pharmaceutically acceptable salt thereof. The nitrogen-containing heterocyclic compound as represented by formula (I), the stereoisomer thereof, or the pharmaceutically acceptable salt thereof provided by the present invention has the activity of inhibiting proliferation of Ba/F3 KRAS-G12D cells, AGS cells, Ba/F3 KRAS-G12V cells expressing KRAS G12D and/or KRAS G12V mutant proteins, and also shows good in vivo tumor suppression activity; the present invention is expected to treat and/or prevent a variety of diseases mediated by KRAS G12D and/or KRAS G12V.

Abstract: Provided is a cooking appliance. The cooking appliance includes a cooking body, an inner pot, and a separation device. The cooking body defines an accommodation cavity. The inner pot defines a cooking cavity. The separation device has a liquid storage cavity and a backflow channel. The backflow channel has a first liquid flowing portion and a second liquid flowing portion. The liquid storage cavity is in communication with the backflow channel through the first liquid flowing portion. The cooking cavity is in communication with the backflow channel through the second liquid flowing portion. The separation device has a liquid inlet portion, and the liquid storage cavity is in communication with the cooking cavity through the liquid inlet portion. The separation device is provided with a flow guide portion at a bottom of the separation device.

Abstract: A mesylate salt of the compound of formula (I), the preparation method thereof, a pharmaceutical composition containing said salt and the use of said salt in treating diseases mediated by activating and resistance mutations of EGFR, in particular cancers, in mammal, in particular human. The mesylate salt of the compound of formula (I) has a high bioavailability in animal, and can remarkably inhibit the growth of transplanted tumors in animal and show a good safety.

Abstract: A mesylate salt of the compound of formula (I), the preparation method thereof, a pharmaceutical composition containing said salt and the use of said salt in treating diseases mediated by activating and resistance mutations of EGFR, in particular cancers, in mammal, in particular human. The mesylate salt of the compound of formula (I) has a high bioavailability in animal, and can remarkably inhibit the growth of transplanted tumors in animal and show a good safety.

Abstract: The present invention relates to pyridinylaminopyrimidine derivatives represented by the following formula (I), and pharmaceutically acceptable salts, preparation process and use thereof, wherein R1, R2, R3, R4, R5, m and A are defined as in the description. Pyridinylaminopyrimidine derivatives of the present invention can selectively inhibit the activity of mutant-type epidermal growth factor receptor (EGFR), have a good inhibition for the cancer cell proliferation, and therefore can be used as a therapeutic agent for treating tumors and relevant diseases.

Abstract: The present invention relates to pyridinylaminopyrimidine derivatives represented by the following formula (I), and pharmaceutically acceptable salts, preparation process and use thereof, wherein R1, R2, R3, R4, R5, m and A are defined as in the description. Pyridinylaminopyrimidine derivatives of the present invention can selectively inhibit the activity of mutant-type epidermal growth factor receptor (EGFR), have a good inhibition for the cancer cell proliferation, and therefore can be used as a therapeutic agent for treating tumors and relevant diseases.

Abstract: The present invention relates to pyridinylaminopyrimidine derivatives represented by the following formula (I), and pharmaceutically acceptable salts, preparation process and use thereof, wherein R1, R2, R3, R4, R5, m and A are defined as in the description. Pyridinylaminopyrimidine derivatives of the present invention can selectively inhibit the activity of mutant-type epidermal growth factor receptor (EGFR), have a good inhibition for the cancer cell proliferation, and therefore can be used as a therapeutic agent for treating tumors and relevant diseases.

Abstract: The present invention relates to pyridinylaminopyrimidine derivatives represented by the following formula (I), and pharmaceutically acceptable salts, preparation process and use thereof, wherein R1, R2, R3, R4, R5, m and A are defined as in the description. Pyridinylaminopyrimidine derivatives of the present invention can selectively inhibit the activity of mutant-type epidermal growth factor receptor (EGFR), have a good inhibition for the cancer cell proliferation, and therefore can be used as a therapeutic agent for treating tumors and relevant diseases.